Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences  by Wei, Yang & Mojsov, Svetlana
FEBS 15043 FEBS Letters 358 (1995) 219-224 
Tissue-specific expression of the human receptor for 
glucagon-like peptide-I: brain, heart and pancreatic forms have the same 
deduced amino acid sequences 
Yang Wei, Svetlana Mojsov* 
Laboratory of Cellular Physiology and Immunology, Rockefeller University, 1230 York Avenue. New York, NY 10021, USA 
Received 18 November 1994 
Abstract Glucagon-like peptide-I(GLP-I), encoded by the glu- 
cagon gene and released from the gut in response to nutrients, is 
a potent stimulator of glucose-induced insulin secretion. In human 
subjects GLP-I exerts its physiological effect as an incretin. The 
incretin effect of GLP-I is preserved in patients with Type II 
diabetes mellitus (NIDDM), suggesting that GLP-I receptor ag- 
onist can be used therapeutically in this group of patients. In these 
studies we addressed the question of whether GLP-I has broader 
actions in human physiology. To investigate this issue we exam- 
ined the tissue distribution of GLP-I receptor using RNAse pro- 
tection assay in order to avoid the cross-reactivities with structur- 
ally related receptors and to increase the sensitivity of detection. 
The riboprobe was synthesized from the human pancreatic GLP-I 
receptor cDNA and used in hybridization experiments with total 
RNA isolated from different human tissues. In addition to the 
pancreas, we found expression of GLP-I receptor mRNA in lung, 
brain, kidney, stomach and heart. Peripheral tissues which are the 
major sites of glucose turnover, such as liver, skeletal muscle and 
adipose did not express the pancreatic form of the GLP-I recep- 
tor. We also cloned and sequenced GLP-I receptor cDNA from 
human brain and heart. The deduced amino acid sequences are 
the same as the sequence found in the pancreas. These results 
indicate that GLP-I might have effects beyond the pancreas, 
including the cardiovascular and central nervous systems where 
a receptor with the same ligand binding specificity is found. 
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I. Introduction 
Glucagon-like peptide-I (GLP-I) is one of the most po- 
tent insulin secretagogues described to date. Its existence and 
structure were deduced from the nucleotide sequence of the glu- 
cagon gene [14]. There is a single mammalian gene and identi- 
cal preproglucagons are expressed in the intestine and the pan- 
creas [5,6]. The amino acid sequence of GLP-I shows structural 
homology to a number of metabolic peptides and neurotrans- 
mitters, such as glucagon, secretin, gastric inhibitory polypep- 
tide (GIP), growth hormone releasing hormone (GHRH) and 
vasoactive intestinal polypeptide (VIP). At least three molecu- 
lar forms of the peptide are released predominantly in the 
intestine following tissue specific posttranslational processing: 
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Abbreviations." GLP-I, insulin releasing forms of the peptide (GLP-I(7- 
37) and GLP-I(7-36)amide); PCR, polymerase chain reaction; RT- 
PCR, reverse transcriptase polymerase chain reaction. 
a 37-amino acid peptide GLP-I(1 37), a 31-amino acid GLP-I 
(7-37) and a 30-amino acid peptide with an amidated carboxyl 
terminal termed GLP-I(7-36)amide [7]. No physiological func- 
tion for the longer GLP-I(1-37) have yet been found. The 
shorter forms of the peptide, GLP-I(7-37) and GLP-I(7-36) 
amide, are indistinguishable in their ability to stimulate insulin 
secretion from the perfused rat pancreas [8], isolated islets 
maintained in cell culture [9,10], healthy human subjects and 
patients with Type II diabetes mellitus (NIDDM)[11 14]. The 
dose of GLP-I(7-37) and/or GLP-I(7-36)amide required to 
trigger insulin secretion is physiologic and glucose dependent 
[8]. In normal human subjects the shorter forms of GLP-I also 
suppressed circulating glucagon and somatostatin levels 
[12,13]. These results provided further experimental evidence 
for the postulated role of the enteroinsular axis in glucose 
homeostasis [15]. They also established the essential role of 
incretins [16], or substances secreted in the gut in response to 
nutrients, in the regulation of secretions of the pancreatic islet 
hormones. Administration of GLP-I(7-37) and GLP-I(7 
36)amide together with a meal in patients with Type II diabetes 
mellitus (NIDDM) eliminated the postpandrial rise in blood 
glucose [11,12]. Most recently, it was found that the incretin 
effect of the shorter form of GLP-I was preserved in patients 
with Type II diabetes mellitus [13]. The results from the clinical 
studies taken together suggested that GLP-I(7-37) and/or 
GLP-I(7-36)amide receptor agonists might be therapeutically 
useful in this group of patients. 
In addition to its metabolic effects on the pancreas, GLP-I(7 
36)amide has other physiological functions. For example, itwas 
recently reported that in rodent species GLP-I(7 36) amide can 
stimulate the secretions of macromolecules from lung airways 
and can produce relaxation of pulmonary artery [17]. The local- 
ization of GLP-I binding sites on airway gland cells, as well as 
on smooth muscle cells in the pulmonary artery is consistent 
with these observations [17]. The brain is another potential 
target issue for GLP-I action. Both preproglucagon, the bio- 
synthetic precursor of GLP-I peptides, and [~25I]GLP-I binding 
sites have been detected in various regions of mouse and rat 
brain, respectively [18 21]. On the basis of these observations 
it might be postulated that, like a number of other peptides 
secreted in the gut, GLP-I could also be considered to be a 
neurotransmitter. This hypothesis raises the question of 
whether the metabolic effects of GLP-I and its effects in the 
central nervous ystem are regulated by similar signal transduc- 
tion pathways. To approach this question in a systematic man- 
ner we investigated the distribution of the GLP-I receptor in 
human tissues using the pancreatic form of the human GLP-I 
receptor cDNA as a molecular probe. 
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Here we report GLP-I  receptor expression in human pan- 
creas, lung, brain, stomach, kidney and heart. We did not detect 
the expression of GLP-I receptor in human liver, muscle and 
adipose tissues. We also show that GLP-I  receptors expressed 
in pancreas, heart and brain have identical deduced amino acid 
sequences. 
2. Experimental 
2.1. Mater&& 
Human total RNA's were obtained from commercial sources (Clon- 
tech, Palo Alto, CA) except for the human adipose tissue total RNA 
which was kindly provided by Dr. Susan Fried. Human glyceraldehyde 
3-phosphate dehydrogenase (HGPDH) cDNA was purchased from 
Clontech and human glucose transporter (GLUT)4 cDNA was a gener- 
ous gift of Dr. G. Bell. 
2.2. Cloning of the human pancreatic GLP-I receptor 
1.8 x 106 plaques from a human pancreatic cDNA library in 2-gtl 1 
vector (Clontech, Palo Alto, CA) were screened with a full length GLP-I 
receptor cDNA cloned from the RIN 1046-38 cell line [22]. Positive 
clones with size greater than 1.5 kb were cloned into pBluescript II
KS(-) vector (Stratagene, La Jolla, CA) and sequenced with Sequenase 
(U.S. Biochemical, Cleveland, OH). From this library we isolated a 
single positive clone that contained the entire sequence of the human 
GLP-I receptor cDNA (HPC10). The nucleotide sequence of HPC10 
has been deposited in the Gene Bank (accession umber U10037). 
2.3. Synthesis of a GLP-I receptor RNA probe 
RNA probes were synthesized as described [23]. Briefly, a 449 bp 
fragment was obtained from the 1,59 kb human GLP-I receptor cDNA 
(HPC10) by digestion with EcoRI and StuI. This fragment contained 
125 bp from the 5'-untranslated region and 324 bp of the 5'-coding 
sequence of GLP-I receptor cDNA. It was subcloned into pBluescript 
II KS(-) vector, and was further digested with BamHI which cleaves 
at position 282. The resulting linear DNA template (1/.tg) was then 
transcribed using standard published procedures [24]. 
2.4. Synthesis of HG3DH and GLUT4 RNA probes 
Human glyceraldehyde 3-phosphate dehydrogenase (HG3DH) and 
human glucose transporter (GLUT4) RNA probes were prepared as 
positive controls for the RNase protection assay. 
(i) HG3DH fragment was obtained by restriction enzyme digest at 
the HindlIl site at positions 1 and 256 in the HG3DH cDNA [25], and 
it was subcloned into pBluescript KS(-) vector. Linear DNA was 
obtained by restriction enzyme digest with XbaI which cleaves at a site 
located in the vector at position immediately preceding the 5'-end of 
HG3DH. 
(ii) A fragment of GLUT4 was obtained by restriction enzyme digest 
with ApaI which cleaves at positions 391 and 1485 of human GLUT4 
cDNA [26]. This fragment was subcloned into pBluescript KS(-) vector 
and further digested with HindllI which cleaves at position 1141. The 
resulting DNA fragment was used as a template for the synthesis of a 
riboprobe. 
The HG3DH and GLUT4 RNA probes were synthesized as de- 
scribed in [24]. 
2.5. RNase protection assay 
In a typical experiment 15/.tg of total RNA from lung, pancreas, 
brain, kidney, liver, stomach, muscle and adipose tissues (or yeast 
tRNA used as a control in every experiment) was mixed with 5 x 105 
cpm of probe in a final volume of 40/11 containing 1× PIPES (40 mM 
PIPES pH 6.7, 400 mM NaCI, 1 mM EDTA pH 8.0), and 50% forma- 
mide. The reaction mixture was heated at 80°C for 5 rain and then 
hybridized at 55°C overnight. Following hybridization, the reaction 
mixture was incubated at 37°C for 15 rain with 300 pl of 10 mM Tris 
(pH 7.5), 5 mM EDTA (pH 8.0), 300 mM NaC1, RNase (20 ktg/ml) and 
RNase T1 (100 U/pl). 10% SDS (20 pl) and Proteinase K (50/11 of 
1 mg/ml) were added for 15 min at 37°C. The solution was extracted 
with an equal volume of phenol/CHCl~, and precipitated with ethanol 
(850 pl). The pellets were collected by centrifugation a d lyophilized to 
dryness. They were dissolved in formamide gel dye (4/tl), heated at 
100°C for 3 min and run on a standard sequencing gel. Results were 
visualized by exposing the gel to an X-ray film, first overnight and then 
for three weeks. The same protocol was used with 60/~g of total RNA 
from lung, pancreas, brain, kidney, liver, stomach and heart issues. All 
the hybridizations were performed at least twice in different experi- 
ments using newly synthesized RNA probes. 
For some tissues different lots of the commercially obtained total 
RNA's were used. Adipose tissue total RNA was obtained from tissue 
samples excised from different anatomical sites. In all hybridizations 
experiments with the adipose tissue we used GLUT4 RNA probe as a 
positive control. Reproducible results were obtained in the multiple 
experiments with all tissues. 
2.6. R T-PCR of the GLP-I receptor cDNA from human brain and heart 
Sequence specific primers used to amplify human brain and heart 
GLP-I receptor cDNA were designed on the basis of the nucleotide 
sequence of the human pancreatic GLP-I receptor cDNA (clone 
HPC10). Primers HP126 (5'-CCATGGCCGGCGCCCCCGG-3') and 
HP772 (5'-CATCCCACTGGTGCTGCT-3') were used to amplify the 
5' region of the brain GLP-I receptor cDNA for the first round of PCR 
and HP126 and HP688 (5'-TGAAGGATGCAAACAGGTTCAG-Y) 
for the second round of PCR (Fig. 3, panel A(b and c)). From these 
reactions we obtained the sequence from position 126 to position 688 
of the brain GLP-I receptor cDNA. To amplify the sequence of GLP-I 
receptor cDNA from position 266 to position 772 we used primers 
HP266 (5'-AGCGCTCCCTGACTGAGGAT-3') (Fig. 3, panel A(d)) 
and HP772, and for the 3'-end from position 696 to 1568 we used 
primers HP696 (5'-AGCATTGTCCGTCTTCAT-3') and HP1568 
(5'-TTGGCCACCCGGCTGCAGCAA-Y) (Fig. 3, panel A(e)). 
To amplify GLP-I receptor cDNA from human heart we used two 
sets of primers: (i) HP126 and HP772 (Fig. 3, panel A(b)) and (ii) HP696 
and HP1568 (Fig. 3, panel A(e)). 
RT-PCR was performed with 200 units of SuperScript II reverse 
transcriptase according to the specifications supplied by Life Technol- 
ogies, Inc. (Gaithersburg, MD). 
Thirty-six cycles of PCR were carried out at 94°C for 40 s, 56°C for 
50 s and 72°C for 90 s. These conditions were applied for the amplifi- 
cation of the fragments of the brain (Fig. 3, panel A(d and e)) and heart 
(Fig. 3, panel A(b and e)) GLP-I receptor cDNA sequences. 
To amplify the 5'-region of the human brain GLP-I receptor cDNA 
primers HPI26 and HP772 (Fig. 3, panel A(b)) were first used for 36 
cycles as described above. The amplified DNA was separated from free 
nucleotides and primers on a GlassMAX DNA isolation Spin Cartridge 
(Gibco-BRL, Gaithersburg, MD), and then reamplified by another 
nested set of primers HP126 and HP688 (Fig. 3, panel A(c)). PCR 
results were analyzed by electrophoresis through a 1% agarose gel. The 
amplified DNA was ligated into pCR vector (In Vitrogen, San Diego, 
CA), using T4 DNA ligase under conditions recommended by the 
manufacturer. They were sequenced on double-stranded DNA by the 
chain termination technique with Sequenase (U.S. Biochemical, Cleve- 
land, OH). 
3. Results 
3.1. Tissue distribution of  the human GLP-I  receptor cDNA 
RNase protection was used to identify tissues in which 
GLP-I  receptor is expressed. We applied this method instead 
of Northern blot analysis in order to improve the sensitivity of 
detection, and to eliminate possible ross-reactivities with other 
structurally related receptors [23]. For the RNase protection 
assay we synthesized an RNA fragment designed to protect a 
168 bp segment of the human GLP-I  receptor mRNA tran- 
script. This hybridization probe was derived from the region of 
the pancreatic human GLP-I  receptor eDNA sequence that 
encodes the extracellular, putative ligand binding domain of the 
receptor, and contains the least structural homologies with the 
other related receptors. In the first round of experiments we 
included in addition to total RNA from human pancreas, total 
RNA's  from human, lung, brain, stomach, kidney and liver. We 
used in the hybridization experiments 60 pg of total RNA 
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Fig. 1. RNase protection assay. A riboprobe synthesized from the 
human pancreatic GLP-I receptor cDNA was hybridized with total 
RNA (60 ug) isolated from human lung, pancreas, brain, kidney, stom- 
ach and liver. The molecular size of the RNA:RNA hybrids was deter- 
mined by gel electrophoresis and visualized by autoradiography after 
exposure to an X-ray film for 21 days. 
isolated from these tissues to establish limits of detection of the 
GLP-I receptor mRNA transcripts. As seen from Fig. 1, we 
detected the expected protected fragment in the samples of total 
RNA from human pancreas, as well as total RNA's from 
human lung, brain, stomach and kidney. There was no band 
in the sample of total RNA from human liver. The protected 
band appeared as a doublet which is a common artifact in 
RNase protection assays usually related to the redundancy at 
the ends of the probe [23]. In all the experiments we used a 
tRNA as a negative control (data not shown). The same pro- 
tected fragment was also detected when 15/2g of total RNA 
isolated from these tissues was used in the hybridization exper- 
iments. As positive controls for the quality of the human brain, 
lung, stomach, kidney and liver total RNA's we used as a 
hybridization probe an antisense RNA fragment which was 
synthesized from human glyceraldehyde 3-phosphate dehydro- 
genase cDNAs (see section 2). All samples contained appropri- 
ate levels of HG3DH mRNA (data not shown). 
The absence of GLP-I receptor mRNA transcripts from 
human liver is in agreement with our earlier experiments in
which we demonstrated that GLP-I(7-37) did not have an effect 
on gluconeogenesis and cAMP levels in rat hepatocytes and did 
not antagonize the gluconeogenic action of glucagon [27]. 
On the basis of these findings we decided to extend our 
experiments and to determine whether other proposed target 
tissues for GLP-I action such as human adipose and muscle [12] 
also express GLP-I receptor mRNA. In these experiments we 
also included total RNA isolated from human heart. As posi- 
tive controls in this set of experiments we used an RNA frag- 
ment synthesized from human glucose transporter 4 (GLUT4) 
cDNA [26] and total RNA from pancreas. Results shown in 
Fig. 2, panel A, demonstrate hat only heart issue was positive 
for GLP-I receptor expression, whereas GLUT 4 was detected 
in all three tissues (Fig. 2, panel B). 
3.2. Cloning and sequencing of the GLP-I receptor cDNA from 
human brain and heart 
Our initial intention was to amplify the full length GLP-I 
receptor cDNA, and for that purpose we used two primers: 
HP126 that corresponds to the sequence of the 5'-untranslated 
end and beginning of the coding sequence, and HP1568 that 
corresponds to the end of the coding sequence followed by the 
3' untranslated region of the pancreatic GLP-I receptor cDNA 
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(Fig. 3, panel A(a)). However, we were unable to amplify any 
fragments using this set of primers (data not shown). These 
results are consistent with our earlier experiments (Y. Wei, and 
S. Mojsov, unpublished results) in which we could not amplify 
full length GLP-I receptor cDNA from the cDNA prepared 
from RIN 104(%38 cell line using primers corresponding to the 
sequence of the 5' and 3' ends of the rat islet GLP-I receptor 
cDNA. For these reasons we decided to use primers that will 
amplify smaller fragments of the brain and heart GLP-I recep- 
tor cDNA with overlapping sequences (Fig. 3, panel A(b) 
through (e)). Using these sets of primers we were able to am- 
plify the expected fragments (0.56 kb, 0.57 kb and 0.87 kb, 
respectively) of GLP-I receptor cDNA from human brain 
(Fig. 3, panel B, lanes (C)-(E)) and heart (0.65 kb and 0.87 kb) 
as shown in Fig. 3, panel C, lanes (B) and (E). 
The nucleotide sequence of the DNA fragments cloned from 
human brain corresponded to the sequence of the human pan- 
creatic GLP-I receptor cDNA, with the exception of few single 
nucleotide substitutions in the following locations of the se- 
quence: (i) 502, a change of G to A; (ii) 526, A to C; (iii) 780, 
A to C; (iv) 871, T to C and (v) 1270, C to T. These differences 
between the pancreatic and brain GLP-I receptor cDNA's 
found at the level of single nucleotides are most likely caused 
by copying errors of Taq polymerase [29] and do not represent 
actual differences. In a similar manner, the nucleotide sequence 
of GLP-I receptor cDNA from human heart contained a single 
nucleotide change in position 788 of T to A. These changes in 
the coding triplets are reflected in differences in the deduced 
amino acid sequences between the pancreatic form of GLP-I 
receptor and the its brain and heart forms (Fig. 4). 
< 168 bp 
GLP-1R 
< 334 bp 
GLUT 4 
Fig. 2. RNase protection assay. Panel (A) A riboprobe synthesized from 
human pancreatic GLP-I receptor cDNA was hybridized with total 
RNA isolated from human pancreas, muscle, adipose (15/.tg) and heart 
(60/2g). Panel (B) A riboprobe synthesized from human GLUT4 cDNA 
[25] was hybridized with total RNA prepared from human adipose, 
muscle and heart (15 pg). The experimental conditions of the assay were 
the same as described in legend to Fig. 1 and in section 2. The arrows 
indicate the expected molecular size of the protected fragments of 
human GLP-I receptor (panel A) and human GLUT4 mRNA tran- 
scripts (panel B). 
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570bp 
HP696 .-> 
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I HP772 
I HP688 
I HP772 
HP696l 
870bp 
I 3 '  HPGLP-1 cDNA 
<--- 
HP1568 
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B. 
M C D E 
C, 
B E 
0.6 kb-> 
Fig. 3. RT-PCR analysis of GLP-I receptor expression i  human brain and heart. Panel A, schematic representation of (a) human pancreatic GLP-I 
receptor cDNA sequence (clone HPC 10) and the position of the oligonucleotide primers used for the PCR amplification fthe brain and heart GLP-I 
receptor cDNA; (b) through (e) expected size of the amplified fragments ofthe brain and heart GLP-I receptor cDNA. Open box represents the coding 
sequence. Numbers on top and bottom of the arrows represent the nucleotide position in the sequence ofthe pancreatic human GLP-I receptor cDNA 
(clone HPCI0). Panels B and C, detection of the amplified fragments ofbrain and heart GLP-I receptor cDNA by agarose gel electrophoresis. Panel 
B, lane M, markers, lanes (C)-(E), the molecular weight of the amplified fragments ofbrain GLP-I receptor cDNA. Panel C, lanes (B) and (E) the 
molecular weight of the amplified fragments of heart GLP-I receptor cDNA. Detected fragments (C)-(E) in Panel B and (B) and (E) in panel C 
correspond to the expected fragments represented in (c) (e) in Panel A. 
4. Discussion 
In our studies we utilized the RNase protection assay in 
order to increase the sensitivity of detection of GLP-I receptor 
mRNA transcripts and to eliminate the cross-reactivities with 
structurally related receptors. The results show that GLP-I 
receptor is expressed not only in human pancreas, but also in 
lung, brain, stomach, kidney and heart. They extend the previ- 
ous findings which detected by Northern blot analysis the ex- 
pression of GLP-I receptor mRNA transcripts only in human 
pancreas [30]. Our results are also in agreement with the find- 
ings of GLP-I receptor expression i  rat lung, brain, stomach 
and kidney [28,31] and further indicate that GLP-I in human 
and rodent species has similar if not identical biological effects. 
The detection of GLP-I receptor in human heart is a novel 
observation and its physiological function in this organ needs 
to be elucidated. 
Our findings suggest hat in humans the shorter forms of 
GLP-I might have more diverse physiological functions than 
previously described, and are of immediate interest in view of 
the ongoing efforts to develop therapeutic agents based on 
GLP-I structure for treatment of disorders of glucose metabo- 
lism manifested in patients with Type II diabetes mellitus. 
In our experiments we were able to detect GLP-I receptor 
mRNA transcripts in total RNA from hum~in pancreas, where 
islet cell population that expresses GLP-I receptor is present in 
about 1-2% of the tissue. The increased sensitivity of RNase 
protection assay utilized in our studies was also confirmed in 
experiments in which we were not able to detect GLP-I receptor 
mRNA transcripts in human heart by Northern blot analysis 
(data not shown). Nonetheless, we did not find expression of 
the GLP-I receptor in tissues which are the major sites of 
glucose turnover, such as liver, skeletal muscle, and adipose. In 
contrast o these findings, other investigators have reported 
metabolic effects of GLP-I in rat adipocytes and rat hepato- 
cytes [32 34]. In addition, pharmacological doses of GLP-I(7- 
36)amide increased glucose utilization in both healthy human 
subjects [35] and patients with insulin dependent diabetes mel- 
litus (IDDM) [12]. These differences can be a result of one or 
more factors. The first one, is that the effects of GLP-I in 
peripheral tissues are mediated through a GLP-I receptor sub- 
type which is different from the pancreatic form of the receptor. 
The second, and not mutually exclusive one, is that GLP-I can 
stimulate other gut derived substances. This could be accom- 
plished through an enteroendocrine loop in the intestine in a 
similar manner as described recently for GIP stimulation of 
GLP-I secretions in rodent species [36]. Finally, we can not 
exclude the possibility that we were unable to detect he expres- 
sion of GLP-I receptor in specialized compartments that make 
up less than 1% of the cell population in human liver, muscle 
Y. Wei, S. Mojsov/FEBS Letters 358 (1995) 219-224 223 
HPGLP- I  
HBGLP- I  
HHGLP- I  
1 MAGAPGPLRLALLLLGMVGRAGPRPQGATVSLWETVQKWREYRRQCQRSL 50 
1 MAGAPGPLRLALLLLGMVGRAGPRPQGATVSLWETVQKWREYRRQCQRSL 50 
1 MAGAPGPLRLALLLLGMVGRAGPRPQGATVSLWETVQKWREYRRQCQRSL 50 
HPGLP- I  
HBGLP-I  
HHGLP-I  
51 TEDPPPATDLFCNRTFDEYACWPDGEPGSFVNVSCPWYLPWASSVPQGHV i00 
51 TEDPPPATDLFCNRTFDEYACWPDGEPGSFVNVSCPWYLPWASSVPQGHV i00 
51 TEDPPPATDLFCNRTFDEYACWPDGEPGSFVNVSCPWYLPWASSVPQGHV i00 
HPGLP- I  
HBGLP- I  
HHGLP- I  
HPGLP- I  
HBGLP- I  
HHGLP- I  
HPGLP- I  
HBGLP- I  
HHGLP- I  
HPGLP- I  
HBGLP-I  
HHGLP- I  
HPGLP- I  
HBGLP- I  
HHGLP- I  
HPGLP- I  
HBGLP- I  
HHGLP- I  
i01 YRFCTAEGLWLQKDNSSLPWRDLSECEESKRGERSSPEEQLLFLY I IYTV 150 
i01 YRFCTAEGLWLQKDNSSLPWRDLSECEESKRGERSSPEEQLLFLY I IYTV 150 
i01 YRFCTAEGLWLQKDNSSLPWRDLSECEESKRGERSSPEEQLLFLY I IYTV 150 
I II 
151 GYALSFSALVIASAILLGFRHLHCTRNYIHLNLFASF ILRALSVF IKDAA 200 
151 GYALSFSALVIASAILLBFRHLHCTRNYIHLNLFASF ILRALSVF IKDAA 200 
151 GYALSFSALVIASAILLGFRHLHCTRNYIHLNLFASF ILRALSVF IKDAA 200 
III 
201 LKWMYSTAAQQHQWDGLLSYLDSLSCRLVFLLMQYCVAANYYWLLVEGVY 250 
201 LKWMYSTAAQQHQWDGLLSYLDSLSCRLVFLLMQYCVAANYYWLLVEGVY 250 
201 LKWMYSTAAQQHQWDGLLSYQDSLSCRLVFLLMQYCVAANYYWLLVEGVY 250 
IV 
251 LYTLLAFSVLSEQWIFRLYVS IGWGVPLLFVVPWGIVKYLYEDEGCWTRN 300 
251 LYTLLAFSVFSEQWIFRLYVS IGWGVPLLFVVPWGIVKYLHEDEGCWTRN 300 
251 LYTLLAFSVLSEQWIFRLYVS IGWGVPLLFVVPWGIVKYLYEDEGCWTRN 300 
V 
301 SNMNYWLI IRLP ILFA IGVNFL IFVRVIC IVVSKLKANLMCKTDIKCRLA 350 
301 SNMNYWLI IRLP ILFA IGVNFL IFVRVIC IVVSKLKANLMCKTDIKCRLA 350 
301 SNMNYWLI IRLP ILFA IGVNFL IFVRVIC IVVSKLKANLMCKTDIKCRLA 350 
VI VI I  
351 KSTLTL IPLLGTHEVIFAFVMDEHARGTLRF IKLFTELSFTSFQGLMVAI  400 
351 KSTLTL IPLLGTHEVIFAFVMDEHARGTLRF IKLFTELSFTSFQGLMVAI  400 
351 KSTLTL IPLLGTHEVIFAFVMDEHARGTLRF IKLFTELSFTSFQGLMVAI  400 
HPGLP- I  
HBGLP- I  
HHGLP- I  
401 LYCFVNNEVQLEFRKSWERWRLEHLHIQRDSSMKPLKCPTSSLSSGATAG 450 
401 LYCFVNNEVQLEFRKSWERWRLEYLHIQRDSSMKPLKCPTSSLSSGATAG 450 
401 LYCFVNNEVQLEFRKSWERWRLEHLHIQRDSSMKPLKCPTSSLSSGATAG 450 
HPGLP- 1 451 SSMYTATCQASCS 464 
HBGLP- 1 451 SSMYTATCQASCS 464 
HHGLP- 1 451 SSMYTATCQASCS 464 
Fig. 4. Composite deduced amino acid sequence of the human brain (HBGLP-I) and heart (HHGLP-I) GLP-I receptor and comparison with deduced 
amino acid sequence of the human pancreatic GLP-I receptor (HPGLP-|), clone HPC10. The lines above the sequence designated I through VII 
represent he putative membrane spanning domains. The amino acid differences between the pancreatic, brain and heart forms of the GLP-I receptors 
are indicated by the bold letters. They are most likely caused by errors in nucleotide incorporation of Taq polymerase during PCR amplification 
(see section 3 and ref. 27). 
and adipose tissues. However, it is highly unlikely that the 
peripheral effects of GLP-I would be mediated through a 
GLP-I receptor which is present only in a very small subgroup 
of cells in this tissues. 
The sequence of the GLP-I receptor is homologous to the 
sequences of the newly identified family of G-protein coupled 
receptors for several endocrine peptides, such as glucagon, se- 
cretin, growth hormone releasing hormone (GHRH), vasoac- 
rive intestinal peptide (VIP), calcitonin and parathyroid 
hormone (PTH) [37]. The highest sequence similarities are 
found in the second and sixth membrane spanning domains, 
while there is very little sequence conservation in the their 
extracellular domains. For these reason it has been postulated 
that they represents the ligand binding domains. The riboprobe 
used in our studies was specific for the putative ligand binding 
domain of the GLP-I receptor and protected the same fragment 
of the receptor in all tissues. Thus, we can postulate that differ- 
ent human tissues express GLP-I receptor with similar if not 
identical ligand binding specificity. To gain further experimen- 
tal evidence in support of this conclusion we cloned and se- 
quenced the GLP-I receptor eDNA from human brain and 
heart. The deduced amino acid sequence of the brain GLP-I 
receptor contained four amino acids that were different from 
the pancreatic form of the receptor, while in the heart the 
difference was in a single amino acid. However, these changes, 
most likely, do not represent actual differences in the pancre- 
atic, brain and heart GLP-I receptor sequences, and are pro- 
duced during the PCR amplification of the brain and heart 
GLP-I receptor eDNA. The recent cloning of GLP-I receptor 
eDNA from rat lung which is identical to the rat pancreatic 
GLP-I receptor eDNA [38] provides additional evidence in 
support of our conclusions. 
Our finding that GLP-I receptor in human pancreas, heart 
and brain have the same amino acid sequences will provide a 
basis for further investigation of the mechanism of interaction 
of the GLP-I receptor with distinct signal transduction path- 
224 Y. Wei, S. MojsovlFEBS Letters 358 (1995) 219-224 
ways present in these tissues. This knowledge isessential for our 
understanding of the physiological role of GLP-I peptides in 
such diverse organs as the human heart and brain. 
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